Questions about COVID-19?

What Patients & Families Need to Know | New Visitor Policy | Guidance for Community Healthcare Providers

A photo of Tracy Glauser.

Associate Director, Cincinnati Children's Research Foundation

Director, Comprehensive Epilepsy Center

Co-Director, Genetic Pharmacology Service

Professor, UC Department of Pediatrics

513-636-4222

513-636-3980

Board Certified

Best Doctors logo

My Biography & Research

Biography

Tracy A. Glauser, MD, is director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center and professor of pediatrics in the University of Cincinnati College of Medicine. Dr. Glauser received his medical degree, cum laude, from Jefferson Medical College in Philadelphia, PA. He completed his residency in pediatrics at the John Hopkins Hospital in Baltimore, MD, and fellowship in child neurology at The Children’s Hospital of Philadelphia, University of Pennsylvania in Philadelphia, PA. Dr. Glauser completed a National Institute of Neurological Disorders and Stroke research fellowship in pediatric neurology and was a fellow in epilepsy and electroencephalography at St. Louis Children’s Hospital, Washington University School of Medicine in St. Louis, Missouri.

Dr. Glauser has authored and co-authored more than 130 articles and book chapters, been involved with the development of six evidence-based guidelines about epilepsy therapy and given over 150 invited lectures throughout the world. He has been the principal investigator on multiple NIH grants. Currently, Dr. Glauser directs the NIH funded Childhood Absence Epilepsy clinical trial involving 32 pediatric centers around the United States. Dr. Glauser’s fields of expertise are pediatric neurology, pediatric epilepsy, clinical pharmacology and pharmacogenetics.

Clinical Interests

Epilepsy; pharmacogenetics; clinical pharmacology

Research Interests

Clinical pharmacology; pharmacogenetics; antiepileptic clinical trials 

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Neurology, Epilepsy, Genetic Pharmacology, Neurology, Clinical Pharmacology

My Education

MD: Jefferson Medical College, Philadelphia, PA, 1985.

Residency: Johns Hopkins Hospital, Baltimore, MD.

Fellowship: St. Louis Children's Hospital, St. Louis, MO.

Certification: Pediatrics, 1990; Neurology (with special competence in child neurology), 1991.

My Publications

Selected Publication

Development of information sharing in language neocortex in childhood-onset drug-resistant epilepsy. Arya, R; Ervin, B; Wilson, JA; Byars, AW; Rozhkov, L; Buroker, J; Horn, PS; Scholle, C; Fujiwara, H; Greiner, HM; et al. Epilepsia. 2019; 60:393-405.

Electrical stimulation mapping of language with stereo-EEG. Arya, R; Ervin, B; Dudley, J; Buroker, J; Rozhkov, L; Scholle, C; Horn, PS; Vannest, J; Byars, AW; Leach, JL; et al. Epilepsy and Behavior. 2019; 99:106395-106395.

Electroencephalographic Reporting for Refractory Status Epilepticus. Sansevere, AJ; Arya, R; Sánchez Fernández, I; Gaillard, WD; Tasker, RC; Lai, YC; Anderson, AE; Tchapyjnikov, D; Chapman, KE; Brenton, JN; et al. Journal of Clinical Neurophysiology. 2019; 36:365-370.

Bridging the childhood epilepsy treatment gap in northern Nigeria (BRIDGE): Rationale and design of pre-clinical trial studies. Aliyu, MH; Abdullahi, AT; Iliyasu, Z; Salihu, AS; Adamu, H; Sabo, U; Garcia, JP; Abdullahi, SU; Mande, A; Xian, H; et al. Contemporary Clinical Trials Communications. 2019; 15:100362-100362.

Investigation of bias in an epilepsy machine learning algorithm trained on physician notes. Wissel, BD; Greiner, HM; Glauser, TA; Mangano, FT; Santel, D; Pestian, JP; Szczesniak, RD; Dexheimer, JW. Epilepsia. 2019; 60:e93-e98.

The onset of pediatric refractory status epilepticus is not distributed uniformly during the day. Sanchez Fernandez, I; Gainza-Lein, M; Abend, NS; Amengual-Gual, M; Anderson, A; Arya, R; Brenton, JN; Carpenter, JL; Chapman, KE; Clark, J; et al. Seizure-European Journal of Epilepsy. 2019; 70:90-96.

A Recurrent Missense Variant in AP2M1 Impairs Clathrin-Mediated Endocytosis and Causes Developmental and Epileptic Encephalopathy. Helbig, I; Lopez-Hernandez, T; Shor, O; Galer, P; Ganesan, S; Pendziwiat, M; Rademacher, A; Ellis, CA; Hümpfer, N; Schwarz, N; et al. The American Journal of Human Genetics. 2019; 104:1060-1072.

Changes in functional organization and functional connectivity during story listening in children with benign childhood epilepsy with centro-temporal spikes. Vannest, J; Maloney, TC; Tenney, JR; Szaflarski, JP; Morita, D; Byars, AW; Altaye, M; Holland, SK; Glauser, TA. Brain and Language. 2019; 193:10-17.

Using EHRs to advance epilepsy care. Mbwana, JS; Grinspan, ZM; Bailey, R; Berl, M; Buchhalter, J; Bumbut, A; Danner, Z; Glauser, T; Glotstein, A; Goodkin, H; et al. Neurology: Clinical Practice. 2019; 9:83-88.

Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Lyden, P; Pryor, KE; Coffey, CS; Cudkowicz, M; Jr, SR N; Song, S; Rost, NS; Clarke Haley, E; Yankey, J; Magee, K; et al. Annals of Neurology. 2019; 85:125-136.